Sanofi has followed in the footsteps of its rivals in the US insulin market with a 78% price cut for its most widely-used Lantus product starting next January. It will restrict out-of-pocket costs ...
Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster Lantus launched today in the US. Basaglar will also undercut Sanofi ...
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...
Free cash flow for 2024 was €6 billion, impacted by Lantus price cuts ... new market entrants potentially impacting market share. Sanofi delivered robust Q4 2024 results with strong growth ...
Hosted on MSN1mon
Sanofi Misses on Q4 Earnings & Sales, Expects Higher Profits in 2025Sanofi SNY reported fourth-quarter 2024 adjusted ... In Others, Toujeo recorded sales of €290 million, up 6.5% year over year. Lantus sales rose 63.4% to €439.0 million. SNY & AZN’s ...
It sells products through independent distributors primarily in India.Sanofi Indias products viz. Lantus, Combiflam, Amaryl and Allegra feature in the top 100 pharmaceutical brands in India.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback